Details of the Drug

General Information of Drug (ID: DMAY7H4)

Drug Name
Valdecoxib
Synonyms
Bextra; COX; Kudeq; Valdyn; Pfizer brand of valdecoxib; Valdecoxib [USAN]; SC 65872; ND-0214; SC-65872; YM-974; Valdecoxib (USAN/INN); P-(5-Methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide; Benzenesulfonamide, 4-(5-methyl-3-phenyl-4-isoxazolyl)-(9CI); 4-(5-Methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide; 4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)benzenesulfonamide; 4-(5-methyl-3-phenyl-4-isoxazolyl) benzenesulfonamide; 4-(5-methyl-3-phenyl-isoxazol-4-yl)benzenesulfonamide; 4-(5-methyl-3-phenylisoxazol-4-yl)benzenesulfonamide; 4-(Methyl-3-phenyl-isoxazol-4-yl)-benzenesulfonamide
Indication
Disease Entry ICD 11 Status REF
Osteoarthritis FA00-FA05 Approved [1], [2]
Therapeutic Class
Antiinflammatory Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 314.4
Topological Polar Surface Area (xlogp) 2.6
Rotatable Bond Count (rotbonds) 3
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 5
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Bioavailability
The bioavailability of drug is 83% [4]
Clearance
The apparent oral clearance of drug is 6 L/h [5]
Half-life
The concentration or amount of drug in body reduced by one-half in 8 - 11 hours [6]
Metabolism
The drug is metabolized via the hepatic [4]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 2.12173 micromolar/kg/day [7]
Unbound Fraction
The unbound fraction of drug in plasma is 0.02% [6]
Vd
The volume of distribution (Vd) of drug is 86 L [5]
Chemical Identifiers
Formula
C16H14N2O3S
IUPAC Name
4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)benzenesulfonamide
Canonical SMILES
CC1=C(C(=NO1)C2=CC=CC=C2)C3=CC=C(C=C3)S(=O)(=O)N
InChI
InChI=1S/C16H14N2O3S/c1-11-15(12-7-9-14(10-8-12)22(17,19)20)16(18-21-11)13-5-3-2-4-6-13/h2-10H,1H3,(H2,17,19,20)
InChIKey
LNPDTQAFDNKSHK-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
119607
ChEBI ID
CHEBI:63634
CAS Number
181695-72-7
DrugBank ID
DB00580
TTD ID
D0L6DA
VARIDT ID
DR01196
INTEDE ID
DR1666

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Prostaglandin G/H synthase 2 (COX-2) TTVKILB PGH2_HUMAN Inhibitor [2]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [8]
Cytochrome P450 2C9 (CYP2C9)
Main DME 		DE5IED8 CP2C9_HUMAN Substrate [9]
UDP-glucuronosyltransferase 1A9 (UGT1A9) DE85D2P UD19_HUMAN Substrate [10]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Osteoarthritis
ICD Disease Classification FA00-FA05
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Prostaglandin G/H synthase 2 (COX-2) DTT PTGS2 7.93E-04 -0.29 -0.34
Cytochrome P450 2C9 (CYP2C9) DME CYP2C9 1.90E-01 -9.81E-03 -5.96E-02
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 1.04E-02 6.29E-02 3.54E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Valdecoxib
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Diclofenac DMPIHLS Moderate Increased risk of hepatotoxicity by the combination of Valdecoxib and Diclofenac. Osteoarthritis [FA00-FA05] [42]
Coadministration of a Drug Treating the Disease Different from Valdecoxib (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Valdecoxib and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [43]
Repaglinide DM5SXUV Moderate Increased risk of hypoglycemia by the combination of Valdecoxib and Repaglinide. Acute diabete complication [5A2Y] [44]
Glibenclamide DM8JXPZ Moderate Increased risk of hypoglycemia by the combination of Valdecoxib and Glibenclamide. Acute diabete complication [5A2Y] [44]
Tolazamide DMIHRNA Moderate Increased risk of hypoglycemia by the combination of Valdecoxib and Tolazamide. Acute diabete complication [5A2Y] [45]
Nateglinide DMLK2QH Moderate Increased risk of hypoglycemia by the combination of Valdecoxib and Nateglinide. Acute diabete complication [5A2Y] [44]
Glipizide DMZA5PQ Moderate Increased risk of hypoglycemia by the combination of Valdecoxib and Glipizide. Acute diabete complication [5A2Y] [44]
Arn-509 DMT81LZ Moderate Increased metabolism of Valdecoxib caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [46]
Metronidazole DMTIVEN Moderate Decreased metabolism of Valdecoxib caused by Metronidazole mediated inhibition of CYP450 enzyme. Amoebiasis [1A36] [47]
Inotersen DMJ93CT Major Increased risk of nephrotoxicity by the combination of Valdecoxib and Inotersen. Amyloidosis [5D00] [46]
Dronedarone DMA8FS5 Moderate Decreased metabolism of Valdecoxib caused by Dronedarone mediated inhibition of CYP450 enzyme. Angina pectoris [BA40] [48]
Bedaquiline DM3906J Moderate Increased risk of hepatotoxicity by the combination of Valdecoxib and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [49]
Voriconazole DMAOL2S Moderate Decreased metabolism of Valdecoxib caused by Voriconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [43]
Budesonide DMJIBAW Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Valdecoxib and Budesonide. Asthma [CA23] [50]
Ofloxacin DM0VQN3 Moderate Additive CNS stimulant effects by the combination of Valdecoxib and Ofloxacin. Bacterial infection [1A00-1C4Z] [51]
Kanamycin DM2DMPO Moderate Increased risk of nephrotoxicity by the combination of Valdecoxib and Kanamycin. Bacterial infection [1A00-1C4Z] [52]
Dalfopristin DM4LTKV Moderate Decreased metabolism of Valdecoxib caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [47]
Clarithromycin DM4M1SG Moderate Decreased metabolism of Valdecoxib caused by Clarithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [47]
Trovafloxacin DM6AN32 Moderate Additive CNS stimulant effects by the combination of Valdecoxib and Trovafloxacin. Bacterial infection [1A00-1C4Z] [53]
Sulfamethoxazole DMB08GE Moderate Decreased metabolism of Valdecoxib caused by Sulfamethoxazole mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [47]
Streptomycin DME1LQN Moderate Increased risk of nephrotoxicity by the combination of Valdecoxib and Streptomycin. Bacterial infection [1A00-1C4Z] [52]
Gemifloxacin DMHT34O Moderate Additive CNS depression effects by the combination of Valdecoxib and Gemifloxacin. Bacterial infection [1A00-1C4Z] [51]
Norfloxacin DMIZ6W2 Moderate Additive CNS stimulant effects by the combination of Valdecoxib and Norfloxacin. Bacterial infection [1A00-1C4Z] [53]
ABT-492 DMJFD2I Moderate Additive CNS depression effects by the combination of Valdecoxib and ABT-492. Bacterial infection [1A00-1C4Z] [51]
Gentamicin DMKINJO Moderate Increased risk of nephrotoxicity by the combination of Valdecoxib and Gentamicin. Bacterial infection [1A00-1C4Z] [52]
Levofloxacin DMS60RB Moderate Additive CNS stimulant effects by the combination of Valdecoxib and Levofloxacin. Bacterial infection [1A00-1C4Z] [51]
Tobramycin DMUI0CH Moderate Increased risk of nephrotoxicity by the combination of Valdecoxib and Tobramycin. Bacterial infection [1A00-1C4Z] [52]
Telithromycin DMZ4P3A Moderate Decreased metabolism of Valdecoxib caused by Telithromycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [54]
Etidronic acid DM1XHYJ Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Valdecoxib and Etidronic acid. Bone paget disease [FB85] [55]
Risedronate DM5FLTY Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Valdecoxib and Risedronate. Bone paget disease [FB85] [55]
Alendronate DMY2KX9 Moderate Increased risk of nephrotoxicity by the combination of Valdecoxib and Alendronate. Bone paget disease [FB85] [55]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Valdecoxib and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [56]
Alpelisib DMEXMYK Moderate Increased metabolism of Valdecoxib caused by Alpelisib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [57]
Drospirenone DM1A9W3 Moderate Increased risk of hyperkalemia by the combination of Valdecoxib and Drospirenone. Contraceptive management [QA21] [58]
Mifepristone DMGZQEF Moderate Decreased metabolism of Valdecoxib caused by Mifepristone mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [59]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Valdecoxib caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [60]
MK-8228 DMOB58Q Moderate Decreased metabolism of Valdecoxib caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [61]
Aprepitant DM053KT Moderate Increased metabolism of Valdecoxib caused by Aprepitant mediated induction of CYP450 enzyme. Depression [6A70-6A7Z] [62]
Nefazodone DM4ZS8M Moderate Decreased metabolism of Valdecoxib caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [47]
Diazepam DM08E9O Moderate Decreased metabolism of Valdecoxib caused by Diazepam mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [47]
Primidone DM0WX6I Moderate Increased metabolism of Valdecoxib caused by Primidone mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [47]
Oxcarbazepine DM5PU6O Moderate Increased metabolism of Valdecoxib caused by Oxcarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [47]
Fosphenytoin DMOX3LB Moderate Increased metabolism of Valdecoxib caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [47]
Rufinamide DMWE60C Moderate Increased metabolism of Valdecoxib caused by Rufinamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [46]
Phenobarbital DMXZOCG Moderate Increased metabolism of Valdecoxib caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [47]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Valdecoxib and Cannabidiol. Epileptic encephalopathy [8A62] [46]
Ethacrynic acid DM60QMR Moderate Antagonize the effect of Valdecoxib when combined with Ethacrynic acid. Essential hypertension [BA00] [63]
Itraconazole DMCR1MV Moderate Decreased metabolism of Valdecoxib caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [47]
Miconazole DMPMYE8 Moderate Decreased metabolism of Valdecoxib caused by Miconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [47]
Eplerenone DMF0NQR Moderate Increased risk of hyperkalemia by the combination of Valdecoxib and Eplerenone. Heart failure [BD10-BD1Z] [64]
Chlorothiazide DMLHESP Moderate Antagonize the effect of Valdecoxib when combined with Chlorothiazide. Heart failure [BD10-BD1Z] [63]
Furosemide DMMQ8ZG Moderate Antagonize the effect of Valdecoxib when combined with Furosemide. Heart failure [BD10-BD1Z] [63]
Amiloride DMRTSGP Moderate Antagonize the effect of Valdecoxib when combined with Amiloride. Heart failure [BD10-BD1Z] [63]
Bumetanide DMRV7H0 Moderate Antagonize the effect of Valdecoxib when combined with Bumetanide. Heart failure [BD10-BD1Z] [63]
Hydroflumethiazide DMVPUQI Moderate Antagonize the effect of Valdecoxib when combined with Hydroflumethiazide. Heart failure [BD10-BD1Z] [63]
Rifapentine DMCHV4I Moderate Increased metabolism of Valdecoxib caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [65]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Valdecoxib and Brentuximab vedotin. Hodgkin lymphoma [2B30] [66]
Delavirdine DM3NF5G Moderate Decreased metabolism of Valdecoxib caused by Delavirdine mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [47]
Efavirenz DMC0GSJ Moderate Increased metabolism of Valdecoxib caused by Efavirenz mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [67]
Saquinavir DMG814N Moderate Decreased metabolism of Valdecoxib caused by Saquinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [47]
Amprenavir DMLMXE0 Moderate Decreased metabolism of Valdecoxib caused by Amprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [47]
Darunavir DMN3GCH Moderate Decreased metabolism of Valdecoxib caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [68]
Fluvastatin DM4MDJY Moderate Decreased metabolism of Valdecoxib caused by Fluvastatin mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [47]
Fenofibrate DMFKXDY Moderate Decreased metabolism of Valdecoxib caused by Fenofibrate mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [43]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Valdecoxib and Mipomersen. Hyper-lipoproteinaemia [5C80] [69]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Valdecoxib and Teriflunomide. Hyper-lipoproteinaemia [5C80] [70]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Valdecoxib and BMS-201038. Hyper-lipoproteinaemia [5C80] [71]
Verapamil DMA7PEW Moderate Decreased metabolism of Valdecoxib caused by Verapamil mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [47]
Indapamide DMGN1PW Moderate Antagonize the effect of Valdecoxib when combined with Indapamide. Hypertension [BA00-BA04] [63]
Hydrochlorothiazide DMUSZHD Moderate Antagonize the effect of Valdecoxib when combined with Hydrochlorothiazide. Hypertension [BA00-BA04] [72]
Conivaptan DM1V329 Moderate Decreased metabolism of Valdecoxib caused by Conivaptan mediated inhibition of CYP450 enzyme. Hypo-osmolality/hyponatraemia [5C72] [73]
Fludrocortisone DMUDIR8 Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Valdecoxib and Fludrocortisone. Hypo-osmolality/hyponatraemia [5C72] [50]
Balsalazide DMO091F Moderate Increased risk of nephrotoxicity by the combination of Valdecoxib and Balsalazide. Indeterminate colitis [DD72] [74]
Brigatinib DM7W94S Moderate Increased metabolism of Valdecoxib caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [75]
PF-06463922 DMKM7EW Moderate Increased metabolism of Valdecoxib caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [76]
Selpercatinib DMZR15V Moderate Decreased metabolism of Valdecoxib caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [77]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Valdecoxib and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [78]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Valdecoxib and Idelalisib. Mature B-cell leukaemia [2A82] [79]
IPI-145 DMWA24P Moderate Decreased metabolism of Valdecoxib caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [80]
Clofarabine DMCVJ86 Moderate Increased risk of hepatotoxicity by the combination of Valdecoxib and Clofarabine. Mature B-cell lymphoma [2A85] [46]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Valdecoxib caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [46]
Ethinyl estradiol DMODJ40 Moderate Decreased metabolism of Valdecoxib caused by Ethinyl estradiol mediated inhibition of CYP450 enzyme. Menopausal disorder [GA30] [81]
Danazol DML8KTN Moderate Decreased metabolism of Valdecoxib caused by Danazol mediated inhibition of CYP450 enzyme. Menstrual cycle bleeding disorder [GA20] [47]
Exjade DMHPRWG Major Increased risk of nephrotoxicity by the combination of Valdecoxib and Exjade. Mineral absorption/transport disorder [5C64] [82]
Deflazacort DMV0RNS Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Valdecoxib and Deflazacort. Muscular dystrophy [8C70] [50]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Valdecoxib caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [46]
Nilotinib DM7HXWT Moderate Decreased metabolism of Valdecoxib caused by Nilotinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [83]
Imatinib DM7RJXL Moderate Decreased metabolism of Valdecoxib caused by Imatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [47]
Dasatinib DMJV2EK Moderate Decreased metabolism of Valdecoxib caused by Dasatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [84]
Modafinil DMYILBE Minor Increased metabolism of Valdecoxib caused by Modafinil mediated induction of CYP450 enzyme. Narcolepsy [7A20] [85]
Polythiazide DMCH80F Moderate Antagonize the effect of Valdecoxib when combined with Polythiazide. Oedema [MG29] [63]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Valdecoxib caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [86]
Aspirin DM672AH Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Valdecoxib and Aspirin. Pain [MG30-MG3Z] [87]
Abametapir DM2RX0I Moderate Decreased metabolism of Valdecoxib caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [88]
Lefamulin DME6G97 Moderate Decreased metabolism of Valdecoxib caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [89]
Prednisone DM2HG4X Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Valdecoxib and Prednisone. Postoperative inflammation [1A00-CA43] [50]
Hydrocortisone DMGEMB7 Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Valdecoxib and Hydrocortisone. Postoperative inflammation [1A00-CA43] [50]
Lonafarnib DMGM2Z6 Moderate Decreased metabolism of Valdecoxib caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [90]
Enzalutamide DMGL19D Moderate Increased metabolism of Valdecoxib caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [91]
Everolimus DM8X2EH Major Increased risk of nephrotoxicity by the combination of Valdecoxib and Everolimus. Renal cell carcinoma [2C90] [92]
Temsirolimus DMS104F Major Increased risk of nephrotoxicity by the combination of Valdecoxib and Temsirolimus. Renal cell carcinoma [2C90] [92]
Gatifloxacin DMSL679 Moderate Additive CNS stimulant effects by the combination of Valdecoxib and Gatifloxacin. Respiratory infection [CA07-CA4Z] [53]
Sulfasalazine DMICA9H Moderate Increased risk of nephrotoxicity by the combination of Valdecoxib and Sulfasalazine. Rheumatoid arthritis [FA20] [74]
Dexamethasone DMMWZET Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Valdecoxib and Dexamethasone. Rheumatoid arthritis [FA20] [50]
Leflunomide DMR8ONJ Major Increased risk of hepatotoxicity by the combination of Valdecoxib and Leflunomide. Rheumatoid arthritis [FA20] [70]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Valdecoxib caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [46]
Larotrectinib DM26CQR Moderate Decreased metabolism of Valdecoxib caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [43]
Methylprednisolone DM4BDON Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Valdecoxib and Methylprednisolone. Solid tumour/cancer [2A00-2F9Z] [50]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Valdecoxib and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [46]
Armodafinil DMGB035 Minor Increased metabolism of Valdecoxib caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [85]
LEE011 DMMX75K Moderate Decreased metabolism of Valdecoxib caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [93]
Prednisolone DMQ8FR2 Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Valdecoxib and Prednisolone. Solid tumour/cancer [2A00-2F9Z] [50]
Disulfiram DMCL2OK Moderate Decreased metabolism of Valdecoxib caused by Disulfiram mediated inhibition of CYP450 enzyme. Substance abuse [6C40] [47]
Naltrexone DMUL45H Moderate Increased risk of hepatotoxicity by the combination of Valdecoxib and Naltrexone. Substance abuse [6C40] [94]
Warfarin DMJYCVW Moderate Decreased metabolism of Valdecoxib caused by Warfarin mediated inhibition of CYP450 enzyme. Supraventricular tachyarrhythmia [BC81] [47]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Valdecoxib caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [95]
Sirolimus DMGW1ID Major Increased risk of nephrotoxicity by the combination of Valdecoxib and Sirolimus. Transplant rejection [NE84] [92]
Tacrolimus DMZ7XNQ Major Increased risk of nephrotoxicity by the combination of Valdecoxib and Tacrolimus. Transplant rejection [NE84] [92]
Tolbutamide DM02AWV Moderate Increased risk of hypoglycemia by the combination of Valdecoxib and Tolbutamide. Type 2 diabetes mellitus [5A11] [45]
Chlorpropamide DMPHZQE Moderate Increased risk of hypoglycemia by the combination of Valdecoxib and Chlorpropamide. Type 2 diabetes mellitus [5A11] [45]
Olsalazine DMZW9HA Moderate Increased risk of nephrotoxicity by the combination of Valdecoxib and Olsalazine. Ulcerative colitis [DD71] [74]
Plazomicin DMKMBES Moderate Increased risk of nephrotoxicity by the combination of Valdecoxib and Plazomicin. Urinary tract infection [GC08] [96]
Triamcinolone DM98IXF Moderate Increased risk of GI mucosal injury/bleeding risk by the combination of Valdecoxib and Triamcinolone. Vasomotor/allergic rhinitis [CA08] [50]
Amiodarone DMUTEX3 Moderate Decreased metabolism of Valdecoxib caused by Amiodarone mediated inhibition of CYP450 enzyme. Ventricular tachyarrhythmia [BC71] [47]
⏷ Show the Full List of 123 DDI Information of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2894).
2 Biochemical mechanisms of New Molecular Entities (NMEs) approved by United States FDA during 2001-2004: mechanisms leading to optimal efficacy and ... Curr Top Med Chem. 2006;6(5):461-78.
3 BDDCS applied to over 900 drugs
4 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
5 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
6 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
7 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8 Simultaneous assessment of drug interactions with low- and high-extraction opioids: application to parecoxib effects on the pharmacokinetics and pharmacodynamics of fentanyl and alfentanil. Anesthesiology. 2003 Apr;98(4):853-61.
9 Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine? Expert Opin Drug Metab Toxicol. 2009 Jun;5(6):607-20.
10 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
11 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
12 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
13 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
14 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
15 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
16 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
17 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
18 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
19 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
20 Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
21 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
22 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
23 Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
24 Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
25 New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
26 A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
27 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
28 Polymorphic expression of UGT1A9 is associated with variable acetaminophen glucuronidation in neonates: a population pharmacokinetic and pharmacogenetic study. Clin Pharmacokinet. 2018 Oct;57(10):1325-1336.
29 Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab Dispos. 2005 Jul;33(7):1027-35.
30 Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma. Invest New Drugs. 2011 Dec;29(6):1511-4.
31 The evolution of population pharmacokinetic models to describe the enterohepatic recycling of mycophenolic acid in solid organ transplantation and autoimmune disease. Clin Pharmacokinet. 2011 Jan;50(1):1-24.
32 The UDP-glucuronosyltransferase 1A9 enzyme is a peroxisome proliferator-activated receptor alpha and gamma target gene. J Biol Chem. 2003 Apr 18;278(16):13975-83.
33 Maternal toxicity of nonsteroidal anti-inflammatory drugs as an important factor affecting prenatal development. Reprod Toxicol. 2009 Sep;28(2):239-44.
34 Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol. 2000 Oct;40(10):1109-20.
35 Membranous nephropathy associated with the relatively selective cyclooxygenase-2 inhibitor, etodolac, in a patient with early rheumatoid arthritis. Intern Med. 2007;46(13):1055-8.
36 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
37 Pfizer. Product Development Pipeline. March 31 2009.
38 Renal effects of nabumetone, a COX-2 antagonist: impairment of function in isolated perfused rat kidneys contrasts with preserved renal function in vivo. Exp Nephrol. 2001;9(6):387-96.
39 Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19.
40 Flurbiprofen, a cyclooxygenase inhibitor, protects mice from hepatic ischemia/reperfusion injury by inhibiting GSK-3 signaling and mitochondrial permeability transition.Mol Med.2012 Sep 25;18:1128-35.
41 Cox-2 inhibitory effects of naturally occurring and modified fatty acids. J Nat Prod. 2001 Jun;64(6):745-9.
42 Product Information. Solaraze (diclofenac topical). Doak Dermatologics Division, Fairfield, NJ.
43 Cerner Multum, Inc. "Australian Product Information.".
44 Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
45 Christensen LK, Hansen JM, Kristensen M "Sulphaphenazole-induced hypoglycemic attacks in tolbutamide-treated diabetics." Lancet 2 (1963): 1298-301. [PMID: 14071924]
46 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
47 Product Information. Bextra (valdecoxib). Pharmacia Corporation, Peapack, NJ.
48 Product Information. Multaq (dronedarone). sanofi-aventis , Bridgewater, NJ.
49 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
50 Buchman AL, Schwartz MR "Colonic ulceration associated with the systemic use of nonsteroidal antiinflammatory medication." J Clin Gastroenterol 22 (1996): 224-6. [PMID: 8724264]
51 Product Information. Factive (gemifloxacin). GeneSoft Inc, San Francisco, CA.
52 Assael BM, Chiabrando C, Gagliardi L, Noseda A, Bamonte F, Salmona M "Prostaglandins and aminoglycoside nephrotoxicity." Toxicol Appl Pharmacol 78 (1985): 386-94. [PMID: 4049389]
53 Davey PG "Overview of drug interactions with the quinolones." J Antimicrob Chemother 22(suppl c) (1988): 97-107. [PMID: 3053579]
54 Product Information. Ketek (telithromycin). Aventis Pharmaceuticals, Bridgewater, NJ.
55 Product Information. Actonel (risedronate). Procter and Gamble Pharmaceuticals, Cincinnati, OH.
56 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
57 Fuhr U, Maier-Bruggemann A, Blume H, et al. "Grapefruit juice increases oral nimodipine bioavailability." Int J Clin Pharmacol Ther 36 (1998): 126-32. [PMID: 9562227]
58 Product Information. Yasmin (drospirenone-ethinyl estradiol) Berlex Laboratories, Richmond, CA.
59 Product Information. Korlym (mifepristone). Corcept Therapeutics Incorporated, Menlo Park, CA.
60 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
61 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
62 Product Information. Emend (aprepitant). Merck & Company Inc, West Point, PA.
63 Muller FO, Schall R, Devaal AC, Groenewoud G, Hundt HKL, Middle MV "Influence of meloxicam on furosemide pharmacokinetics and pharmacodynamics in healthy volunteers." Eur J Clin Pharmacol 48 (1995): 247-51. [PMID: 7589049]
64 Abdel-Haq B, Magagna A, Favilla S, Salvetti A "Hemodynamic and humoral interactions between perindopril and indomethacin in essential hypertensive subjects." J Cardiovasc Pharmacol 18 (1991): s33-6. [PMID: 1725198]
65 Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
66 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
67 Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
68 Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
69 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
70 EMEA "EMEA public statement on leflunomide (ARAVA) - severe and serious hepatic reactions.".
71 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
72 McCarthy JT, Torres VE, Romero JC, et al "Acute intrinsic renal failure induced by indomethacin." Mayo Clin Proc 57 (1982): 289-96. [PMID: 6952058]
73 Product Information. Vaprisol (conivaptan). Cumberland Pharmaceuticals Inc, Nashville, TN.
74 Novis BH, Korzets Z, Chen P, Bernheim J "Nephrotic syndrome after treatment with 5-aminosalicylic acid." Br Med J (Clin Res Ed) 296 (1988): 1442. [PMID: 3132281]
75 Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
76 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
77 Product Information. Retevmo (selpercatinib). Lilly, Eli and Company, Indianapolis, IN.
78 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
79 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
80 Product Information. Copiktra (duvelisib). Verastem, Inc., Needham, MA.
81 Bailey DG, Arnold JMO, Spence JD "Grapefruit juice and drugs - how significant is the interaction." Clin Pharmacokinet 26 (1994): 91-8. [PMID: 8162660]
82 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
83 Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
84 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
85 Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
86 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
87 Abdel-Rahman MS, Reddi AS, Curro FA, Turkall RM, Kadry AM, Hansrote JA "Bioavailability of aspirin and salicylamide following oral co-administration in human volunteers." Can J Physiol Pharmacol 69 (1991): 1436-42. [PMID: 1777842]
88 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
89 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
90 Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
91 Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
92 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
93 DSouza DL, Levasseur LM, Nezamis J, Robbins DK, Simms L, Koch KM "Effect of alosetron on the pharmacokinetics of alprazolam." J Clin Pharmacol 41 (2001): 452-4. [PMID: 11304902]
94 Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
95 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
96 Farag MM, Mikhail MR, Abdel-Meguid E, Abdel-Tawab S "Assessment of gentamicin-induced nephrotoxicity in rats treated with low doses of ibuprofen and diclofenac sodium." Clin Sci 91 (1996): 187-91. [PMID: 8795442]